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Fatal case of newborn Lassa fever virus
infection mimicking late onset neonatal
sepsis: a case report from northern Nigeria
Taofik Oluwaseun Ogunkunle1, Surajudeen Oyeleke Bello1, Chinwe Immaculata Anderson1, Rashida Musa1,
Rasaq Olaosebikan2 and Abdulazeez Imam3*

Abstract
Background: Lassa fever is a zoonotic viral infection endemic to the West Africa countries. It is highly fatal during
pregnancy and as such reports of neonatal onset Lassa fever infections are rare in scientific literature. We report a
fatal case of Lassa fever in a 26-day-old neonate mimicking the diagnosis of late-onset neonatal sepsis.
Case presentation: The patient is a 26-day-old neonate who was admitted with a day history of fever, poor
feeding, pre-auricular lymphadenopathy and sudden parental death. He was initially evaluated for late onset
neonatal sepsis. He later developed abnormal bleeding and multiple convulsions while on admission, prompting
the need to evaluate for Lassa fever using reverse transcription polymerase chain reaction (RT-PCR). He died 31 h
into admission and RT-PCR result was positive for Lassa fever.
Conclusions: Neonatal Lassa fever infection is highly fatal and can mimic neonatal sepsis. High index of suspicion
is needed particularly for atypical presentations of neonatal sepsis in Lassa fever endemic areas.
Keywords: Lassa fever, Neonatal sepsis, Newborn, Newborn mortality, Nigeria

Background
Lassa fever is an acute viral haemorrhagic illness endemic
to the West African sub-region and first discovered in
Northern Nigeria [1]. The disease is transmitted to humans
via contact with food or other items contaminated with
urine or faeces from the natural reservoir, rodents [2].
Mastomys natalensis (natal multimammate mouse) was
initially thought to be the only known reservoir, there is
however evidence in literature to suggest other rodent
species, for example, Mastomys erythroleucus (Guinea
multimammate mouse), Hylomyscus pamfi (African wood
mouse) and Mus baoulei (the pygmy mice) [3, 4]. Humanto-human transmission also occurs through contact with
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infected persons secretions or through vertical transmission from mother to child [5].
The disease has an incubation period of 6 to 21 days
and is symptomatic in about 20% of infected persons,
who commonly present with symptoms similar to other
more common tropical ailments such as malaria and
typhoid fever [6]. Lassa fever is also highly fatal to the
developing foetus and fatality rates as high as 87% have
been described in fetuses and neonates with vertically
acquired Lassa fever infection [7]. As such, description
of neonatal onset Lassa fever infection is scarce in the
literature.
Nigeria has experienced repeated Lassa fever outbreaks
and is currently experiencing an epidemic with 979
recorded cases and a case fatality rate of 19.2% as of 26
April, 2020 [8]. In this report, we present a unique case
of fatal Lassa fever infection in a 26-day-old baby
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admitted to the special care baby unit of a referral
tertiary health center in North-Central Nigeria with an
initial diagnosis of late-onset neonatal sepsis. Our report
emphasizes the importance of a high index of suspicion
for Lassa fever in atypical presentations of neonatal
sepsis especially during outbreaks.

Case presentation
The case is a 26-day-old term male neonate who was
brought to the neonatal unit of the Dalhatu Araf Specialist Hospital by his maternal grandmother with complaints of high grade continuous fever, poor feeding and
facial swelling which were noticed a day prior to presentation. The baby was said to have been delivered at
home. Both the baby’s parents had died about a week
earlier from a febrile illness spanning about 2 weeks and
the grandmother initially admitted to having limited
knowledge regarding the exact nature of their illness.
The family had resided in a rural part of town and was
of low socio-economic status.
On initial physical examination, the infant was fully
conscious but febrile with an axillary temperature of
38 °C and weighed 2.8 kg. He was pale and had a leftsided pre-auricular lymphadenopathy with pustular
rashes around his perineal area. He was not jaundiced
and was not in respiratory distress. An initial diagnosis
of late onset neonatal sepsis was made, and the patient
was prescribed empirical antibiotics – intravenous cefotaxime (50 mg/kg, 12-hourly) and ampicillin/cloxacillin
combination (50 mg/kg, 6-hourly). This was based on
the local unit protocol for babies admitted from the
community. His bedside random blood sugar check was
normal (7.4 mmol/L) and a packed cell volume was 30%.
His samples were sent for full blood count and blood
culture (Table 1).
About 14 h into admission, his fever peaked at 39.4 °C,
and he subsequently experienced multiple convulsive
episodes with profound irritability. He was later noticed
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to have developed a hyperemic conjunctiva with facial,
neck and truncal petechiae. A timeline of his symptoms
is detailed in Fig. 1. As a result of the progress of his
symptoms, the admitting team considered the possibility
of meningitis and disseminated intravascular coagulopathy and suspected Lassa fever due to an existing
outbreak in the state. Intravenous cefotaxime was then
substituted with ceftriaxone (100 mg/kg/day) due to better cerebrospinal fluid penetration of the latter. He was
also started on intravenous phenobarbitone for seizure
control. On further direct questioning of his maternal
grandmother, she revealed that the baby’s mother had
died from a bleeding associated febrile illness around the
time of delivery while his father also died few days
before the mother’s demise from a similar illness. A
blood sample was sent to the Nigerian Centre for
Disease Control national reference laboratory in Abuja,
located in a neighbouring state. The baby was isolated
and transfused with fresh whole blood and stringent
infection prevention protocol was activated. He subsequently developed shallow breathing and intermittent
apnea and died about 31 h into admission despite active
resuscitation. Virology report using reverse transcription
polymerase chain reaction (RT-PCR) was made available
48 h after the baby’s demise and was positive for Lassa
fever virus.
The epidemiology unit of the hospital commenced
contact tracing and identified close contacts of the index
case. All contacts (health workers and family members)
were stratified into three risk category according to the
National guideline on Lassa fever case management [9].
Seven persons were categorized as high risk; two
doctors, three nurses and two health attendants and they
were all commenced on oral ribavirin for post-exposure
prophylaxis using the Irrua regimen (100 m/kg in 2
divided doses on day 1, then 25 mg/kg/day on day 2 to
7, and 12.5 mg/kg on day 8 to 10) [9]. Three out of the
seven high risk contacts completed the seven-day therapy

Table 1 Laboratory investigation results of index case
Laboratory investigations

Values/Results

Reference ranges/remark

2300 per mm3

4000–10 000 per mm3

a

Complete blood count
White cell count
Neutrophils

38% (874 per mm3)

Lymphocytes

57% (1311 per mm3)

Platelet

179 000 per mm3

150 000–400 000 per mm3

Packed cell volume

30%

> 35%

Blood film appearance

Hypochromic, microcytic

Blood culture

No growth after 7 days of incubation

HIV screening

Negative

Random blood sugar readings

5.6 mmol/L, 7.4 mmol/L, 10.6 mmol/L

a

Sample obtained at presentation

Normal
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Fig. 1 Timeline for index case clinical presentation

while the rest stopped the medication after day two to
three of therapy due to experience of side effects. None of
the ‘no risk’ and ‘low risk’ category developed symptoms
during the 21 days of observation and none of the ‘high
risk’ contact was positive for Lassa fever virus.

Discussion and conclusions
The Lassa fever virus is an RNA virus from the
Arenaviridae family. Lassa fever, although has been in
existence for decades but still has no vaccine. Geographically the disease is endemic to West African countries
and outbreaks have occurred in Nigeria, Guinea, Liberia
and Sierra Leone, where the disease is endemic [6].
Imported cases to the United States and Europe have
also been described in literature [10]. Risk factors for
acquiring the virus include residence in rural areas or
communities with poor sanitation, crowded living conditions, family contacts of infected persons and health
workers [2, 11].
Lassa fever affects all age groups but the clinical
course of paediatric Lassa fever is poorly described in
literature [12]. Available evidence suggests paediatric
illness presents with an acute febrile illness, generalized
edema, abdominal distension, and bleeding [13]. In other
literature, paediatric patients with Lassa fever have also
been shown to present with acute abdomen, convulsive
episodes or in severe disease, clinical features of a swollen baby syndrome which is characterized by widespread
edema, abdominal distention, and bleeding [14–16].
There is a dearth of knowledge of clinical course for
neonates with Lassa fever virus infection because of an
increased risk of adverse pregnancy outcomes in
vertically acquired infection [17]. Moreover, typical adult
and older paediatric age symptoms such as malaise, sore

throat, retrosternal pain and myalgia are impossible to
elicit in neonates.
In the index case, high grade fever, lymphadenopathy,
convulsions and uncontrolled bleeding were consistent
with the existing symptoms described in older paediatric
populations [13, 16]. In addition, the baby presented
with an atypical onset of symptoms at the 25th day of
life which is outside the known maximum incubation
period of 21 days. The managing team initially made a
diagnosis of late-onset neonatal sepsis (LONS) and
following onset of bleeding and convulsions, considered
well known complications of LONS such as disseminated intravascular coagulation (DIC) and meningitis.
The diagnosis of Lassa fever was explored due to the
current national Lassa fever epidemic and suspicious
death of both the neonates parents shortly after delivery.
This has important implications, as Lassa fever is hyperendemic in Nigeria and can present in the absence of
epidemics. In addition, to observing universal precaution
for all patients, clinicians and health workers attending
to cases of neonatal sepsis might need a higher index of
clinical suspicion particularly in neonates presenting
with complications of DIC and meningitis or a history of
sudden parental death following delivery. This underscores the importance of taking a detailed medical
history and being familiar with local clinical case definitions in resource-poor settings and also taking necessary
steps when these clinical case definitions are met. Early
exploration of the cause of death of parents of the index
case might have helped in early diagnosis and treatment,
as the parents’ clinical history of death following a febrile
illness with bleeding already provided adequate case
definition for Lassa fever irrespective of an epidemic.
Nevertheless, the high index of suspicion prevented potential for nosocomial acquired Lassa fever among health
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workers and other patients. Nosocomial outbreaks of
Lassa fever have been frequently reported in West Africa
due to poor adherence to infection control practices and
standard universal precaution measures [13].
Results of RT-PCR for the index case was obtained 48
h after demise as the RT-PCR sample had to be sent to a
national reference laboratory several kilometers away.
This highlights challenges faced by health professionals
in real-time treatment and management of Lassa fever in
endemic resource-poor settings and suggests the need
for further capacity strengthening and decentralization
of Lassa fever testing. In the short to medium term
however, research and development might need to focus
on development of rapid testing kits for Lassa fever that
can be used as point-of-care before confirmation at regional molecular laboratory level.
Our reported case resulted in fatality, but there is
some evidence from a case report and a retrospective cohort study to suggest positive newborn outcomes in few
pregnant mothers [17, 18]. In these cases, Lassa fever
was diagnosed early and treated in the third trimester of
pregnancy and these were reports of mothers who delivered in specialist or tertiary-level health facilities [17, 18].
The mother of our index participant delivered in at home
and was not identified as a probable Lassa fever case. This
raises a key issue about knowledge on symptomatology of
Lassa fever among the general populace in Nigeria and
this might need to be addressed by local health policy
makers.
Neonatal Lassa fever is highly fatal and when presenting in the neonatal period might be indistinguishable
from neonatal sepsis. A high index of clinical suspicion
and detailed histories are crucial in neonatal Lassa fever
diagnosis in endemic settings and this should be entertained even in the absence of outbreaks. Improving
capacity for laboratory identification of the virus is
important for early diagnosis and treatment in these settings. Public enlightenment programs on Lassa fever are
need to educate the general public on clinical recognition of Lassa fever.
Abbreviations
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sepsis; RT-PCR: Reverse transcription polymerase chain reaction
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